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1. Introduction
Proliferation of mammalian cells is strictly regulated by growth stimulation. Cell prolifera‐
tion is stimulated not only by normal growth stimulation but also by abnormal growth stim‐
ulation originated from oncogenic changes. Such abnormal growth stimulation leads to
tumorigenesis, if not properly guarded by appropriate cellular response. Cells are endowed
with intrinsic tumor suppressor pathways to protect cells from tumorigenesis upon such on‐
cogenic threat [1]. The tumor suppressor pathways halt cell proliferation either by restrain‐
ing cell cycle progression or by inducing apoptosis (programmed cell death) in case of being
unable to stop aberrant cell cycle progression. Consequently, the cell-fate, whether to grow,
stop growing or die, is dependent on the balance between growth-promoting effects origi‐
nated from oncogenic changes and growth-suppressive effects mediated by the tumor sup‐
pressor pathways upon oncogenic changes (Figure 1). When the tumor suppressor
pathways are disabled by further oncogenic changes, the balance of cell-fate determination
shifts from growth suppression to proliferation, and cells start deregulated proliferation,
leading to tumorigenesis. Among the intrinsic tumor suppressor pathways, two major path‐
ways are the RB pathway and the p53 pathway. Both pathways are important for induction
of cell cycle arrest or apoptosis [2]. In addition, accumulating evidence indicates that the tu‐
mor suppressor TAp73, a member of the p53 family, also plays crucial roles in tumor sup‐
pression by inducing apoptosis independent of p53 [3, 4].
The transcription factor E2F, the main target of the RB pathway, plays crucial roles in cell cycle
progression by activating growth-promoting genes [5]. In this regard, E2F is thought to mediate
growth-promoting effects originating from normal growth stimulation and oncogenic changes.
Supporting this notion, E2F could be an oncoprotein [6]. On the other hand, recent studies indi‐
cate that E2F also plays crucial roles in activation of the major intrinsic tumor suppressor path‐
© 2013 Ozono et al.; licensee InTech. This is an open access article distributed under the terms of the Creative
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ways by sensing oncogenic changes, halting cell proliferation by inducing cell cycle arrest or
apoptosis. Supporting this notion, E2F could also be a tumor suppressor [7]. Taken together,
these observations indicate that E2F is located at the center of the balance between cell prolifera‐
tion and cell cycle arrest or apoptosis, determining the cell-fate upon oncogenic changes (Figure
1). E2F can be regarded as a double-edged sword in cell growth control. In this chapter, we will
describe the major intrinsic tumor suppressor pathways and activation of the tumor suppressor
pathways by E2F upon oncogenic changes. We will focus on how E2F differentially regulates
expression of target genes upon normal growth stimulation and oncogenic changes that have
completely opposite roles in cell-fate determination, to grow, stop or die.
Figure 1. To grow, stop or die? The balance between the activity of growth-promoting pathways and tumor suppressor
pathways determines the cell fate upon oncogenic changes. E2F is located at the center of the balance (see also Figure 6).
2. Major tumor-suppressor pathways
2.1. The RB pathway (CDK inhibitor–Cyc/CDK–RB)
The retinoblastoma gene (RB1) is the first identified tumor suppressor gene [8]. Individuals
with heterozygous deletion or mutation of the RB1 gene are susceptible to retinoblastoma in
early life by additional deletion or mutation of the other allele. The RB1 gene product pRB, to‐
gether with its relatives, p107 and p130, comprises a family of pocket proteins [9, 10] (Hereafter
we refer all pocket proteins to RB, and the RB1 gene product to pRB). The main target of RB is the
transcription factor E2F, which plays central role in cell proliferation by activating growth-pro‐
moting genes including those required for DNA replication and cell cycle progression [9]. In
quiescent phase, RB binds to E2F and suppresses transcriptional activity of E2F. Moreover, RB
recruits various chromatin-modifying factors, such as histone deacetylases (HDACs) [11] and
histone methyl transferase SUV39H1 [12] to actively suppress expression of E2F target genes.
Hence the main role of RB in tumor suppression is thought to be suppression of cell prolifera‐
tion through suppression of E2F target gene expression. Growth stimulation induces expres‐
sion of cyclins and activates cyclin dependent kinases (CDKs), which are called accelerators and
engines in cell cycle progression, respectively. CDKs, in turn, inactivate RB by phosphorylation,
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leading to expression of E2F target genes by releasing them from suppression by RB during G1
to S phase cell cycle progression (Figure 2) [13]. In contrast, growth-suppressive signals such as
contact inhibition and DNA damage induce expression of CDK inhibitors, which are called
brakes in cell cycle progression owing to their ability to inhibit activity of CDKs. Suppression of
CDKs keeps RB in hypo-phosphorylated form, which binds to and inhibits E2F. Consequently,
the activity of E2F to activate growth-promoting genes is controlled by the activity of RB, which
is regulated by CDKs and CDK inhibitors. The pathway converging to RB, including CDKs and
CDK inhibitors, is referred to the RB pathway.
Whether a cell progresses one round of the cell cycle or not is determined at the restriction
point, which is located at late G1 phase of the cell cycle. Once a cell passed through the re‐
striction point, it is programmed that the cell cycle automatically proceeds to the end of M
phase. Thus, whether a cell proliferates or not is determined by whether the cell passes
through the restriction point or not. Two major determinants whether a cell passes through
the restriction point or not are E2F activity and cyclin dependent kinase activity, which is
induced by E2F through activation of the Cyclin E (CycE) gene [14]. Since E2F plays essential
roles in passing through the restriction point, RB can be regarded as a gatekeeper in cell cy‐
cle progression by controlling E2F activity. Hence disruption of the RB pathway and conse‐
quent activation of E2F is thought to be an essential event for tumorigenesis [2]. Actually,
deletion or mutation of the RB1 gene is observed in about 30% of cancers. Moreover, defects
in the RB pathway upstream of RB such as overexpression of CycD and dysfunction of CDK
inhibitors such as p16INK4a are frequently observed in other cancers retaining RB1 [2]. It is
predicted that all cancers have at least some defect in the RB pathway.
The RB pathway plays essential roles in tumor suppression by inducing cell cycle arrest or
cellular senescence through suppression of the activity of E2F. As described below, disrup‐
tion of the RB pathway reinforces cell cycle arrest by induction of CDK inhibitor p21Cip1 ex‐
pression through the p53 pathway or p27Kip1 expression. When cells failed to induce cell
cycle arrest, apoptosis is triggered through the p53 pathway or TAp73, a p53 family mem‐
ber, which activates various pro-apoptotic genes.
Figure 2. The regulatory mechanism of the transcription factor E2F by the RB pathway.
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2.2. The p53 pathway (ARF–p53–cell cycle arrest or apoptosis related effectors)
The tumor suppressor p53 is a transcription factor that is activated by a variety of stress sig‐
nals, including DNA damage, hypoxia and various oncogenic changes including aberrant
activation of E2F [15]. In response to such stress signals, p53 induces either cell cycle arrest
or apoptosis. Cell cycle arrest is mainly mediated through activation of the CDK inhibitor
p21Cip1 gene [16], whose product suppresses wide range of CDKs. Apoptosis is mainly medi‐
ated through activation of the Bax and BH3 only family genes, whose products destabilize
mitochondrial membrane to facilitate cytochrome c release, which triggers apoptotic cas‐
cades of caspase activation.
Since p53 plays crucial roles in induction of cell cycle arrest or apoptosis, the expression
level  of  p53  is  kept  low  by  rapid  ubiquitin/proteasome-dependent  degradation,  mainly
caused  by  Mdm2  (mouse  double  minute  2,  Hdm2  in  humans),  which  is  often  overex‐
pressed in many cancers [15].  Mdm2 is  E3 ubiquitin ligase,  which directly binds to p53
and  promotes  p53  degradation.  Mdm2  also  inhibits  TP53  mRNA  translation  [17].  The
Mdm2  gene  is  a  target  of  p53,  forming a  negative-feedback loop to  control  the  level  of
p53 [18]. Another negative regulator of p53 is MdmX, also known as Mdm4. MdmX has
recently  emerged as  a  discrete  critical  negative  regulator  of  p53 [19].  Though MdmX is
not  a  direct  target  of  p53,  structure  of  MdmX is  significantly  similar  to  that  of  Mdm2.
MdmX is reported to enhance p53 ubiquitination by altering the substrate preference of
the Mdm2, thereby indirectly regulating p53 [20].
Regarding response to oncogenic stresses, a potent activator of p53 is the tumor suppressor
ARF (alternative reading frame, known as p14 in humans and as p19 in rodents) [2]. ARF
directly binds to and sequesters Mdm2 to nucleoli, stabilizing p53 that leads to the expres‐
sion of its target genes [21]. The pathway including upstream and downstream of p53 is re‐
ferred to the p53 pathway. Of note, the ARF gene is a direct target of E2F [22] and this E2F-
ARF interaction connects the RB pathway and the p53 pathway, enabling efficient tumor-
suppressive response. When the RB pathway is disrupted by oncogenic changes, E2F is
activated to induce ARF gene expression, leading to activation of the p53 pathway, which
inhibits oncogenic cell growth by inducing cell cycle arrest or apoptosis (Figure 3). There‐
fore, disruption of both of the tumor suppressor pathways powerfully shifts the cell-fate de‐
termination balance to proliferation (Figure 1) and is thought to be essential to induce
deregulated cell proliferation that leads to tumorigenesis. Indeed, about 50% of cancers car‐
ry TP53 mutations or deletion and most cancers have defects in the p53 pathway including
those in upstream and downstream of p53.
2.3. The TAp73 pathway (E2F–TAp73–pro-apoptotic targets)
The tumor suppressor TAp73 is a homologue of p53 and can induce apoptosis independent‐
ly of p53 [3, 4, 23]. The TP73 gene encodes two isoforms, TAp73 and DNp73, which are driv‐
en by different promoters. DNp73 lacks the transactivation (TA) domain and counteracts
TAp73 and p53 [24]. Thus DNp73 is anti-apoptotic. The TAp73 gene is thought to be a tumor
suppressor gene and is known to be a target of E2F1 [3, 4, 25]. Similarly to p53, TAp73 is
activated by both oncogenic changes and DNA damage [26, 27] and TAp73 target genes
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partly overlap with those of p53, such as the PUMA and NOXA genes [28, 29] that are cru‐
cial for induction of apoptosis. Moreover, TAp73 can induce apoptosis in the absence of p53
[3, 4]. Therefore, TAp73 seems to back-up the important tumor suppressive function of p53.
Figure 3. E2F activates major intrinsic tumor suppressor pathways.
3. The transcription factor E2F
The transcription factor E2F was originally identified as a cellular DNA-binding protein,
which mediate E1A-dependent activation of the adenovirus E2 promoter [30]. Members of
E2F family are downstream targets of the tumor suppressor RB and make repressor com‐
plexes with RB that keep cells in quiescent state [9, 10]. Though E2F plays central roles in
cell proliferation by activating growth-promoting genes, certain members of E2F can induce
apoptosis [15]. In this paragraph, we will describe three points as follows (1) E2F family
members, the role of them in cell cycle progression, cell cycle arrest and apoptosis. (2) Regu‐
latory mechanism of E2F. (3) E2F target genes, to better understand the regulatory mecha‐
nism of cell-fate determination mediated through E2F.
3.1. E2F family members
E2F consists of eight family members (E2F1-E2F8). E2F1-E2F5 are bound by their repressor
RB family proteins through RB binding domain. E2F1-E2F5 activate transcription when free
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from RB and repress transcription when bound by RB. E2F1-E2F3a are induced at G1/S
boundary and activate transcription free from RB. In contrast, E2F3b-E2F5 are expressed all
through the cell cycle and play main roles in transcriptional repression in G0/G1 bound by
RB. E2F6-E2F8 repress transcription independently of RB. Hence E2F family members are
divided into two groups: activator E2Fs (E2F1-E2F3a) and repressor E2Fs (E2F3b-E2F8). Ac‐
tivator E2Fs play major roles in activation of target genes involved in growth promotion,
growth suppression and induction of apoptosis. Repressor E2Fs are roughly divided into
two groups; E2F3b-E2F5, which make repressor complex together with RB, and recently
identified E2F6-E2F8, which function independently of RB.
Figure 4. Structure of E2F family members. E2F1-E2F6 bind to their target promoter with binding partner DP proteins
through dimerization domain. E2F7 and E2F8 have two DNA binding domains and make homodimers or E2F7/E2F8
heterodimer.
A structural characteristic of activator E2Fs (E2F1-E2F3a) is longer N terminal region, which
does not exist in repressor E2Fs (E2F3b-E2F6). Expression of E2F1-E2F3a is induced by E2Fs
themselves [31]. When growth stimulation inactivates p130 by phosphorylation through ac‐
tivation of CycD/Cdk4 or CycD/Cdk6, repressor E2Fs (E2F4 and E2F5) are released from
p130 and activates the E2F1-E2F3a genes. E2F1-E2F3a in turn replace E2F4 and E2F5, and ac‐
tivate growth-promoting genes including E2F1-E2F3a themselves. Each activator E2F has
preferential roles in cell cycle progression and induction of apoptosis. p107 preferentially
make complexes with E2F4-E2F5 in G1/S to S phases.
E2F1 is generally thought to be the most powerful transcriptional activator of pro-apoptotic
genes among activator E2Fs. Overexpression of E2F1 in tissue culture cells alone can induce
cell cycle progression in otherwise quiescent fibroblasts [32]. Overexpression of E2F1 can be
oncogenic in vitro [33, 34] and in vivo [6]. In contrast, E2F1 is dispensable for cell cycle pro‐
gression, since E2F1 knockout mice are viable. On the other hand, over expression of E2F1 in
cancer cell lines leads to apoptosis [35]. E2F1 also plays a key role in induction of cellular
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senescence by activating the ARF-p53 pathway, when overexpressed in human normal fi‐
broblasts [36]. Moreover, E2F1 null mice resulted in tumorigenesis [7]. Taken together, E2F1
seems to play the most important roles in tumor suppression among activator E2Fs by acti‐
vating genes involved in apoptosis and cell cycle arrest.
E2F2 has 46% overall amino acid sequence similarity to E2F1 [37] and is thought to play
roles in both cell proliferation and tumor suppression. E2F2 null mice exhibit increased pro‐
liferation of hematopoietic cells and frequently develop autoimmunity and tumors [38, 39].
In tumor suppression, E2F2 plays major roles in suppression of Myc-induced T cell lympho‐
magenesis. Inactivation of neither E2F1 nor E2F3 had no effect on tumor progression in T
cells, and only loss of E2F2 accelerated lymphomagenesis [40].
E2F3 is thought to be the most important activator E2F in cell proliferation. Although E2F1
or E2F2 null mice are viable and tumor-prone, E2F3 null mice are typically embryonic lethal
in pure background [41] or show partially penetrant embryonic lethality in mixed back‐
ground [42]. Although mouse embryonic fibroblasts (MEFs) with combined knockout of
E2F1 and E2F2 proliferate, those with combined knockout of E2F1, E2F2 and E2F3 fail to
proliferate and can not re-enter the cell cycle [5]. The E2F3 locus encodes two isoforms,
E2F3a and E2F3b, a truncated variant of E2F3 in its N-terminus [43, 44]. Although both
E2F3s partly overlaps their roles in cell cycle progression [45], E2F3a is expressed in G1/S to
S phases and is thought to play crucial roles on cell proliferation, while E2F3b is expressed
equivalently in quiescent and proliferating cells, and associates with pRB, representing the
predominant E2F-pRB complex in quiescent cells [44, 46]. E2F3b also plays roles in myogen‐
ic differentiation by promoting gene expression related to differentiation [47].
Figure 5. Roles of activator E2Fs in cell-fate determination. E2F1 plays crucial roles in induction of apoptosis. E2F3 is
thought be essential for cell proliferation. It is predicted that the character of E2F2 is in the middle of E2F1 and E2F3.
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E2F4 and E2F5 were cloned by their association with p107 and p130, and are significantly
detected in quiescent cells [48, 49]. Knockout mice of either E2F4 or E2F5 are viable [50-52].
E2F4 knockout mice are runted and display defects in late stage of maturation. In addition,
these mice present reduced thickness of the gut epithelium and developmental craniofacial
defects. E2F5 knockout mice develop hydrocephalus after birth apparently due to increased
secretion of cerebrospinal fluid by the choroid plexus. E2F4 and E2F5 double knockout mice
die before birth because of developmental defects, suggesting that E2F4 and E2F5 have some
redundant functions during development [53]. Cells lacking E2F4 and E2F5 are unable to
stop cell cycling upon growth-suppressive signals such as TGF-β treatment, suggesting that
E2F4 and E2F5 are major repressor E2F in restraining cell cycle progression. These two E2Fs
are thought to be important for cell cycle exit and terminal differentiation.
E2F6 does not possess RB binding domain. As predicted from the structure, E2F6 contrib‐
utes gene silencing independent of RB [54] and is predicted to make repressor complex with
polycomb proteins [55]. Consistent with this, E2f6-/- animals display overt homeotic trans‐
formations of the axial skeleton that are strikingly similar to the skeletal transformations ob‐
served in polycomb deficient mice [56]. E2F6 is reported to bind the same E2F-repressor site
as E2F4, suggesting E2F6 may partly overlaps its function as transcriptional repressor with
E2F4 in S phase [57].
E2F7 and E2F8 are thought to function as transcriptional repressors independently of RB
proteins. An important target of E2F7 and E2F8 is the E2F1 gene. E2F7 and E2F8 knockout
mice are embryonic lethal, at least in part, due to apoptosis caused by inability to down reg‐
ulate expression of E2F1, leading to activation of p53 [58]. Recent report showed that E2F7
and E2F8 promote angiogenesis through transcriptional activation of the VEGFA promoter
with hypoxia inducible factor 1 (HIF1) [59].
3.2. Regulatory mechanism of E2F
E2F1 through E2F6 associate with DP family proteins (DP1 or DP2) to form heterodimeric
complexes that bind to DNA in a sequence-specific manner (consensus sequence: TTTC/GG/
CCGC). E2F7 and E2F8 have two DNA binding domains and do not require DP proteins for
binding to DNA. E2F7 and E2F8 make homodimer or E2F7/E2F8 heterodimer to bind to the
target [58].
Transcriptional activity of E2F1 through E2F5 is suppressed by binding of RB family pro‐
teins. pRB preferentially binds E2F1 through E2F3, whereas p107 and p130 preferentially
bind E2F4 and E2F5. However, pRB can also bind E2F4, depending on the cellular circum‐
stances. E2F6 through E2F8 can repress transcription independently of pRB family proteins
[10, 60]. In quiescent phase, E2F3b/pRB, E2F4/p130 and E2F5/p130 repress promoters of E2F
target genes. Upon growth stimulation, activated CycD/Cdk4 and CycD/Cdk6 phosphory‐
late pRB and p130, inhibiting their binding to the E2Fs and allowing accumulation of the
free E2Fs [31]. This release from repression conferred by the pRB family proteins is the pri‐
mary activation step for induction of E2F target genes. In this context, E2F3b, E2F4 and E2F5
mainly act as repressors together with the pRB family proteins during G0/G1 phases. Ex‐
pression of E2F1, E2F2 and E2F3a is induced at the G1/S boundary by E2F itself, and activate
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the growth related genes, including the CycE gene. CycE activates Cdk2, whose activity is
essential for initiating DNA replication, and drive cells into S phase [31]. In late S phase, Cy‐
cA/Cdk2 complex represses the transcriptional activity of E2F/DP complex by phosphoryla‐
tion, which releases the complex from the binding element [61].
3.3. E2F target genes
Classical E2F targets are genes involved in DNA replication and cell cycle progression. In
addition to these, recent studies with DNA microarray and chromatin immunoprecipitation
(ChIP) identified a variety of E2F targets. These include genes involved in DNA repair,
checkpoint, differentiation, development, metabolism, micro RNAs, apoptosis, cell cycle ar‐
rest and others.
DNA replication
E2F regulates expression of most of the genes involved in initiation of DNA replication:
the  ORC1  (origin  recognition  complex1),  CDC6,  MCM  (maintenance  of  minichromosome)  2-7,
ASK  and CDC45  genes.  These factors are assembled into pre-replication complex,  which
is activated by CycE/Cdk2 to initiate DNA replication [31].  Cdt1 also plays crucial  roles
in  initiation  of  DNA replication  and is  negatively  regulated  by  geminin.  The  Cdt1  and
geminin  genes  are  both E2F targets  [62].  Genes,  which code for  machineries  responsible
for  DNA replication,  are  classical  E2F targets.  These  include the  DHFR  (dihydrofolate  re‐
ductase),  DNA polymerase  α,  thymidine  kinase,  thymidylate  synthase  and PCNA (proliferating
cell nuclear antigen) [53].
DNA repair, checkpoint
E2F target genes related to DNA repair are the Rad51, MSH2 and MLH1 genes, which are
involved in homologous recombination repair and mismatch repair [63]. E2F target genes
related to checkpoint are the ATM, Chk1, Mad3, Bub1, Claspin and RanBP1 genes [53, 64-67].
It is expected that E2F regulates these DNA repair and checkpoint genes to prepare machi‐
neries to quickly respond in case of emergency.
Cell cycle progression
E2F induces expression of genes, which play major roles in induction of S phase, such as the
CycE and activator E2F (E2F1-E2F3a) genes themselves [31]. Also, the upstream negative reg‐
ulators of pRB, the Emi1 and Skp2 genes are E2F targets [68, 69]. The genes, which encode
CycA, Cdc2 (CDK1), CycB and B-myb that are important for S and G2/M phase progression,
are also E2F targets [53]. Repressor E2Fs, E2F7 and E2F8 genes are reported to be targets of
E2F1 that promote embryonic development by suppressing E2F1-p53 induced apoptosis,
forming a negative feedback loop. Although c-Myc is reported as a target of E2F [70], E2F
may play a role in suppression of c-Myc expression upon negative growth signals [71].
Development and differentiation
E2F  also  regulates  expression  of  genes  involved  in  development  and  differentiation.
The  Firizzled  homologs1-3,  Homeobox  and  TGF  genes  are  shown  to  be  targets  of  E2F
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[53].  It  is  reported  that  overexpression  of  E2F1-3  induced  various  genes  involved  in
development  and  differentiation  [72].  Interestingly,  although  E2F7  and  E2F8  are  gener‐
ally  regarded  as  transcriptional  repressors,  a  recent  study  reported  the  roles  of  E2F7
and E2F8 in transcriptional  activation of  genes such as  VEGFA as written before [59].
Cellular metabolism
Recent work reported that E2F1 and pRB are required for repression of genes implicated in
oxidative metabolism [73]. E2F1 repressed key genes that regulated energy homeostasis and
mitochondrial functions in muscle and brown adipose tissue, and E2F1 null mice had a
marked oxidative phenotype. Their work suggests a metabolic switch from oxidative to gly‐
colytic metabolism that responds to stressful conditions.
Micro RNAs
Accumulating evidence indicates that expression of E2F is regulated by microRNAs and
that E2F also induces expression of microRNAs [74]. One of the major microRNAs regulated
by E2F is miR-17~92. miR-17~92 is a negative regulator of E2F1-E2F3 and is also a target of
E2F1-E2F3, constructing a fail-safe mechanism to regulate E2F activity. E2F seems to be rig‐
orously controlled by many miRNAs, suggesting that E2F activity must be strictly control‐
led for appropriate cell cycle progression.
Apoptosis and cell cycle arrest
E2F can activate genes involved in apoptosis and cell cycle arrest, which are inconvenient
for cell proliferation. Regulatory mechanism of these growth-suppressive genes by E2F is
yet to be elucidated, especially regarding regulation of cell growth versus tumor suppres‐
sion in response to normal growth stimulation and oncogenic changes. The caspase3, caspase7
and Apaf1 genes, which code for apoptotic machineries, are direct targets of E2F [53]. Cas‐
pases are expressed as inactive precursors (procaspases), and expression of procaspases and
Apaf-1 alone does not necessarily induce apoptosis. These apoptotic machineries require up‐
stream signals to be activated to induce apoptosis. Expression of these two pro-apoptotic
E2F targets and all E2F targets mentioned above is induced by growth stimulation. Thus, ex‐
pression of the pro-apoptotic machinery by growth stimulation is thought to be fail-safe
mechanism to induce apoptosis in case of emergency. We refer these E2F target genes,
whose expression is induced by growth stimulation, to ‘typical E2F targets’. Typical E2F tar‐
gets are activated by growth stimulation, which physiologically inactivates RB by phosphor‐
ylation and activates E2F by release from repression.
In contrast to typical E2F targets, we identified three E2F targets, which are not activated by
growth stimulation. These include the tumor suppressor ARF, TAp73 and CDK inhibitor
p27Kip1 genes. As described below, these genes are critically important in tumor suppression.
We describe the regulatory mechanism of the tumor suppressor ARF, TAp73 and CDK in‐
hibitor p27Kip1 genes by E2F in next paragraph.
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Figure 6. E2F activates both growth-promoting genes and growth- suppressive genes, including E2F itself. It is pre‐
dicted that the expression levels of E2F targets, related to growth- promotion or growth- suppression, decide the bal‐
ance of cell-fate determination.
4. Deregulated E2F
Since E2F1-E2F3a are activated by growth stimulation, it is generally thought that their tar‐
get genes are all activated by growth stimulation. However, E2F1-E2F3a also activate genes
involved in cell cycle arrest or apoptotic, which are inconvenient for cell growth. It has yet to
be elucidated how E2F regulates genes involved in cell cycle arrest or apoptosis, regarding
normal cell growth and tumor suppression.
Since all E2F targets are thought to be activated by growth stimulation, it is surprising that
our previous work identified three growth suppressive E2F targets, which were not activat‐
ed by growth stimulation at all in human normal fibroblasts [75-77]. In contrast, these E2F
targets were activated by deregulated E2F activity induced by overexpression of E2F1 or
forced inactivation of pRB. Overexpression of E2F1 generates exceeding amount of exoge‐
nously introduced E2F1, which becomes out control by RB proteins. Forced inactivation of
pRB induces endogenous deregulated E2F activity out control by pRB. We refer these
growth suppressive E2F targets, which are not activated by growth stimulation but are acti‐
vated by deregulated E2F, to ‘atypical E2F targets’. These atypical E2F targets include the
tumor suppressor ARF and TAp73 genes and the CDK inhibitor p27Kip1 gene These three
atypical E2F target genes play major roles in tumor suppression. ARF is an upstream activa‐
tor of the tumor suppressor p53. CDK inhibitor p27Kip1 activates the RB pathway by inhibit‐
ing CDKs. TAp73 is the tumor suppressor, which can induce apoptosis in dependently of
p53. Our observations suggest that E2F activity induced by RB dysfunction, one of major on‐
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cogenic changes, has distinct function from that induced by growth stimulation in activating
target genes (Figure 7).
E2F activity induced by RB dysfunction activates both typical and atypical E2F targets. In
contrast, E2F activity induced by growth stimulation activates only typical E2F targets and
interestingly, not atypical E2F targets. Both of the E2Fs are similar in the sense that they are
released from repression by RB. However, it is shown that growth stimulation does not to‐
tally inactivate pRB and some portion of activator E2Fs is still in complex with pRB [78].
Moreover, the RB1 gene is an E2F target [79] and expression of pRB is increased in G1/S to S
phases [80]. Indeed, the amount of activator E2Fs/pRB complex rather increases in G1/S to S
phases, as examined by gel mobility shift assay [78]. This observation indicates that E2F ac‐
tivity induced by growth stimulation is still under control of RB. In contrast, E2F activity in‐
duced by dysfunction of RB is thought to be out of control by RB. Here, we refer E2F
activated by growth stimulation to ‘physiological E2F’ and that by dysfunction of RB to ‘de‐
regulated E2F’. Our findings indicate that deregulated E2F is functionally different from
physiological E2F.
In this paragraph, we describe the regulatory mechanism of atypical E2F targets by deregu‐
lated E2F and discuss about the characteristics of deregulated E2F activity regarding its role
in tumor suppression.
Figure 7. Atypical E2F target genes are specifically activated by deregulated E2F activity through specific E2F respon‐
sive elements.
4.1. Atypical E2F targets
The first atypical E2F target identified was the ARF gene [75]. ARF is the major activator of
p53 pathway and links the RB and p53 tumor suppressor pathways [22], playing crucial
roles in tumor suppression. Consistent with this notion, deletion, mutation or silencing of
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the ARF gene is frequently observed in cancers. Moreover, Arf null mice are highly prone to
tumorigenesis [81]. Various oncogenic signals are able to elicit the activation of the ARF
gene. Overexpression of adenovirus E1a or E2F1 in primary mouse embryonic fibroblasts
(MEFs) rapidly induces ARF gene expression and p53-dependent apoptosis [16]. Myc over‐
expression and oncogenic mutant Ras are also strong activators of the ARF gene and combi‐
nation of absence of Arf in mice severely impaired the tumor suppressive activity of p53
[82]. Arf promoter seems to monitor these oncogenic signals as shown by ARF promoter-
GFP transgenic model, in which GFP expression was observed in tumors induced by Myc or
Ras but not in normal growing tissues [83]. Other studies elucidated that ARF also restrains
cell growth independently of p53, interacting with other factors [84]. Taken together, the
ARF gene plays crucial roles in tumor suppression through p53-dependent and independent
pathways.
The  CDK  inhibitor  p27Kip1  is  an  upstream  regulator  of  the  RB  pathway  and  known  to
contribute to the ability of pRB to induce cell-cycle arrest, differentiation and senescence
[85-87].  There is cross regulation between p27Kip1  and pRB. p27Kip1  enhances pRB growth
suppressive function by inhibiting Cyc/CDK, keeping pRB in hypo-phosphorylated form.
pRB increases the amount of p27Kip1  by sequestrating Skp2, a component of E3 ubiquitin
ligase complex,  which promotes degradation of  p27Kip1  [86].  pRB also known to cooper‐
ate with APC/Ccdh1,  another E3 ubiquitin ligase,  to induces Skp2 degradation, stabilizing
p27Kip1  [88].  Taken together,  pRB and p27Kip1  seem to  keep close  relationship  in  the  RB
pathway  to  efficiently  suppress  aberrant  cell  proliferation.  Indeed,  our  previous  study
showed that inactivation of RB by adenovirus E1a increased BrdU (bromodeoxyuridine)-
positive cells  much earlier  in p27Kip1-/-  MEFs than in wild type MEFs [66].  These results
support the notion that p27Kip1  plays important roles in the RB pathway to suppress cell
cycle progression induced by oncogenic changes.
The  tumor  suppressor  TAp73  gene  had  been  identified  as  a  direct  target  of  E2F  using
cancer  cell  lines  [4].  We  found that  the  TAp73  gene  was  activated  by  deregulated  E2F
but  not  by  physiological  E2F  in  human normal  fibroblasts  [77].  TAp73  is  a  p53  family
member  and plays  important  roles  in  tumor suppression with  its  other  family  member
p53 and p63.  All  of  the three genes express differentially spliced isoforms [89,  90].  Two
major isoforms are TA isoforms, which retain transactivation (TA) domain,  and delta N
(DN) isoforms, which lack TA domain. Since these family members activate their targets
as tetramers and DN isoforms lack transactivation (TA) domain, DN isoforms have dom‐
inant-negative properties  [24].  Although p53 is  deleted or mutated in half  of  all  human
cancers,  deletion or mutations of  p73 and p63 occur rarely [91,  92].  Rather over expres‐
sion of DN form of p73 and p63 are commonly observed in many cancers, such as over
expression of DNp73 isoform in gliomas and carcinomas of the breast and the colon [93,
94],  and that  of  DNp63 isoform in bladder  carcinomas [95].  Each DN isoform can sup‐
press  all  three  types  of  TA forms [92,  96,  97].  Therefore,  it  is  expected that  tumor-sup‐
pressive  TA  isoforms  are  suppressed  by  DN  isoforms  in  many  cancers.  This  could
explain why deletion or  mutations of  the TP73  and TP63  genes are rare.  TAp73  can in‐
duce apoptosis independently of p53. Moreover, TAp73 knockout mice are tumor prone,
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infertile, sensitive for carcinogen-induced tumorigenesis and defective for maintenance of
genomic  stability  [98].  The  TAp73  gene  is  activated  by  various  stress  signals  including
deregulated E2F and DNA damage.  These  observations  suggest  that  TAp73 contributes
to  tumor suppression in  addition to  the  p53 pathway in  response to  various  oncogenic
changes.
Accumulating evidence indicates that the three atypical E2F targets explained above play
crucial roles in tumor suppression, by activating the RB pathway, the p53 pathway and the
p53 independent pathway. Taken together, deregulated E2F seems to be critically important
for activating major intrinsic tumor-suppressor pathways in responding to oncogenic
changes to suppress tumorigenesis (Figure 8).
Figure 8. Deregulated E2F plays important roles in activating major tumor suppressor pathways (RB, p53 and TAp73
pathways) by activating the ARF, p27Kip1 and TAp73 genes.
4.2. Distinct transcriptional regulatory mechanism mediated by deregulated E2F
ARF, p27Kip1 and TAp73 exert its effects when expressed unlike pro-apoptotic targets, which
are expressed as inactive precursors such as pro-caspases. Thus the regulation of expression
of these genes is critically important for tumor suppression. The finding that these genes are
specifically activated by deregulated E2F but not by physiologically activated E2F indicates
that there is a mechanism to specifically respond to oncogenic changes to suppress tumori‐
genesis, while allowing normal cell growth upon normal growth stimulation.
We first identified the tumor suppressor ARF gene as an atypical E2F target [75]. In our
studies, we used human normal fibroblasts (HFFs or WI-38) to examine the responsiveness
of each growth-suppressive E2F target to physiological and deregulated E2F. This is because
most of previous studies used cancer cell lines and were unable to examine responsiveness
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of E2F target genes to normal growth stimulation. To induce physiological E2F, we used se‐
rum stimulation, common growth stimulation for fibroblasts. To induce deregulated E2F ac‐
tivity, we used ectopically expressed E2F1 or forced inactivation of RB either by adenovirus
E1a, which binds to and inactivates all RB family proteins, or shRNA against RB1 (shRB),
which represses the expression of pRB. The latter (adenovirus E1a and shRB) is expected to
induce endogenous deregulated E2F activity.
Ectopically expressed E2F1, adenovirus E1a and shRB induced ARF gene expression in RT-
PCR, and activated ARF promoter in reporter assay. However, serum stimulation, which
physiologically activates E2F, did not induce ARF gene expression or activate ARF promoter
under the condition that CDC6 gene (one of typical E2F targets involved in DNA replica‐
tion) expression was significantly induced and CDC6 promoter was clearly activated. These
results indicate that the ARF gene is specifically activated by deregulated E2F but not by
physiological E2F. Promoter analyses identified the E2F responsive element of ARF promot‐
er (EREA), which specifically responds to deregulated E2F activity. Interestingly, the se‐
quence of EREA was composed of only GC repeat and lacked T stretch. This is in contrast to
that of consensus E2F binding motif, which is composed of T stretch and GC repeat
(TTTG/CC/GCGC) in typical E2F targets. In addition, the location of EREA was far upstream
from transcription start site compared to that of typical E2F sites, which is within 100 bp
from transcription start site in most cases. Moreover, our gel mobility shift assay and ChIP
assay showed that EREA specifically binds ectopically expressed E2F1 but not physiological
E2F1 induced by serum stimulation, both in vitro and in vivo, respectively. Taken together,
these observations suggest that the ARF gene is specifically activated through EREA by de‐
regulated E2F activity, triggered by ectopically expressed E2F1 or forced inactivation of RB,
but not by physiological E2F activity, induced by serum stimulation (Figure 7).
A later study showed that ARF promoter lacking EREA was still activated by overexpression of
E2F1 [99]. Our further analyses of ARF promoter identified multiples of EREA-like elements in
ARF promoter. It seems that, although EREA is the major E2F responsive element in ARF pro‐
moter, it is not the sole responsive element and multiple EREA-like elements co-operate to spe‐
cifically respond to deregulated E2F activity (manuscript in preparation).
Defects in the RB pathway activate E2F out of control by RB, promoting abnormal cell
growth. In response to such oncogenic insults, deregulated E2F activates the ARF gene, lead‐
ing to activation of p53 to protect cell from tumorigenesis. For induction of tumorigenesis,
the p53 pathway must be disabled by further oncogenic changes. Indeed, defects in the p53
pathway are observed in almost all cancers. It is expected that the presence of deregulated
E2F be tolerated in cancer cells by further inactivation of the p53 pathway. We thus exam‐
ined the existence of deregulated E2F activity in RB1 deficient cancer cell lines and in nor‐
mal growing fibroblasts. When we introduced constitutively active form of pRB into RB1
deficient cancer cell lines (5637, Saos-2 and C-33 A) and normal growing fibroblasts (WI-38
and HFF), activity of EREA and ARF promoter were decreased in RB1 deficient cancer cell
lines, but not in normal growing fibroblasts. These results showed that deregulated E2F ac‐
tivity specifically exists in RB1 deficient cancer cell lines but not in normal growing fibro‐
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blasts. The presence of deregulated E2F activity may serve as a useful marker to
discriminate cancer cells from normal growing cells.
Our search for new E2F targets with subtraction method identified the CDK inhibitor p27Kip1
gene as an atypical E2F target [66]. p27Kip1 plays important roles in cell cycle arrest by inhib‐
iting Cyc/CDKs. Using reporter assay, we showed that EREK (E2F responsive element of
p27Kip1) was responsible for specifically sensing deregulated E2F activity in human normal
fibroblasts and that EREK was specifically activated in the RB1 deficient cancer cell lines
[76]. Consistent with EREA, the location of EREK was far upstream compared to typical E2F
binding sites. Interestingly, the sequence of EREK contained T in addition to GC repeat and
is rather similar to that of typical E2F binging site. However, EREK bound deregulated E2F1
but not physiological E2F1 in ChIP assay, showing that its character was similar to EREA.
These results suggest that not only the sequence of E2F responsive elements, but also the se‐
quence around the responsive elements may be important for discriminating deregulated
E2F activity from physiological E2F activity. There is also a possibility that structure of the
whole promoter might also affect the discrimination.
Third atypical E2F target is the tumor suppressor TAp73 gene [77]. TAp73 promoter specifi‐
cally responded to deregulated E2F activity through four ERE73s (E2F responsive elements
of TAp73), which were specifically activated by deregulated E2F activity. The sequences of
ERE73s contained T stretch and were similar to that of typical E2F binding sites. Important‐
ly, our ChIP assay showed that bindings of ectopically expressed ‘exogenous’ E2F1 and de‐
regulated ‘endogenous’ E2F1 induced by adenovirus E1a were detected on ERE73s, but not
that of physiological E2F1 induced by serum stimulation. Thus, although the sequences of
ERE73s were similar to or almost same as that of typical E2F binding sites, the characters of
both were completely different. ERE73s were specifically activated by deregulated E2F ac‐
tivity and specifically bound to both ‘exogenous’ and ‘endogenous’ deregulated E2F1. These
results support the notion that both sequences of the E2F binding site and its flanking region
may be important for discriminating deregulated E2F activity from physiological E2F activi‐
ty. Consistent with EREA and EREK, reporter assay showed that ERE73s were also activated
in the RB1 deficient cancer cell lines and not in normal fibroblasts. Moreover, reintroduction
of the constitutive active from of pRB by recombinant adenovirus reduced the expression of
the TAp73 gene in all the cancer cell lines in RT-PCR, indicating that the cancer cell lines har‐
bor deregulated E2F activity that activates the endogenous TAp73 gene.
Interestingly, our unpublished data suggest that not only the RB1 deficient cancer cell lines
but also cancer cell lines retaining pRB harbor deregulated E2F activity. Activity of ERE73s
and expression of the TAp73 gene were suppressed by introduction of the constitutive active
form of pRB in cancer cell lines retaining pRB. These results suggest the possibility that E2F-
mediated transcriptional program can sense defects in the RB pathway, not only pRB itself
but also upstream regulators of pRB. Taken together, deregulated E2F activity might be‐
come a universal means to discriminate cancer cells (may be regardless of the presence of
pRB) from normal growing cells.
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4.3. Difference between deregulated E2F and physiologically activated E2F
Deregulated E2F and physiologically activated E2F are similar in a sense that both are ‘re‐
leased from RB’. However, there is a functional difference between deregulated E2F and
physiologically activated E2F. Deregulated E2F activates both typical and atypical E2F tar‐
gets. In contrast, physiologically activated E2F activates typical E2F targets but not atypical
E2F targets. Why atypical E2F targets are activated by deregulated E2F and not by physio‐
logically activated E2F? What is the difference between deregulated E2F and physiologically
activated E2F? Deregulated E2F is totally ‘out of control’ by RB due to dysfunction of the RB
pathway. In contrast, physiologically activated E2F is temporarily released from RB, predict‐
ed to be ‘under control’ of RB. During normal cell growth, activator E2Fs are induced at
G1/S boundary of the cell cycle. At the point, it is generally believed that pRB is phosphory‐
lated and inactivated. However, pRB is not totally inactivated at the point. Previous studies
indicate that the RB1 gene is an E2F target [79] and expression of pRB is increased in G1/S to
S phases [80]. Moreover, the amount of activator E2Fs/pRB complex rather increases at G1/S
boundary as shown by gel mobility shift assay [78], indicating that some portion of pRB is
still active and is regulating the activity of activator E2Fs. Thus, physiologically activated
E2F is still under control by pRB. It is likely that activity of activator E2Fs is strictly control‐
led by degree of phosphorylation of pRB dependent on the activity of CDKs, reflecting the
strength of growth stimulation. There must be difference between activation of E2F out of
control by pRB and activation of E2F under control by pRB. Our studies of regulatory mech‐
anism of atypical target promoters by E2F elucidated the four different points between regu‐
lation of typical E2F target promoter and that of atypical E2F target promoter.
1. Although sequences of EREK and ERE73s resemble that of typical E2F binding sites, se‐
quence of EREA is different from that of typical E2F sites. The sequence of consensus
E2F binding motif of typical E2F targets is composed of T stretch and GC repeat
(TTTG/CC/GCGC). EREA is composed of only GC repeat and lacks T stretch. Difference in
binding sequence suggests the possibility that there may be a difference in factors,
which recognize the sequence and bind.
2. In all three cases, location of E2F responsive elements of atypical E2F targets is far from
the transcriptional start site compared to that of typical E2F binding sites in typical E2F
targets. In the case of typical E2F targets, location of E2F binding sites is within 100 bp
from transcriptional start site in most cases. Typical E2F targets are under repression by
E2F/RB complex in quiescent phase and are released from repression upon growth
stimulation. Close proximity of E2F binding sites to transcriptional start site may be re‐
quired for this mode of regulation. In contrast, atypical E2F targets are not under re‐
pression by E2F/RB complex and literally activated by deregulated E2F. E2F responsive
elements of atypical E2F targets behave as enhancer elements, which can function from
distance.
3. Deregulated E2F1 bound to EREA, EREK and ERE73s and physiologically activated
E2F1 did not bind to these elements as shown by ChIP assay. In the case of EREA, it is
also shown that repressor type E2F4 does not bind to EREA. This observation is com‐
patible with the observation that these atypical E2F targets are not under repression by
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E2F/RB. The fact that deregulated E2F bind to atypical E2F targets, while physiological
E2F does not bind to atypical E2F targets, suggest that there is difference in binding be‐
havior between deregulated E2F and physiologically activated E2F.
Figure 9. Differences in E2F regulation of target promoters between deregulated E2F and physiological E2F. (1) Se‐
quence of the atypical E2F responsive elements and surrounding regions are different from that of typical E2F targets.
(2) E2F responsive elements of the atypical E2F targets locate far upstream from transcriptional start sites compared to
that of typical E2F targets. (3) E2F responsive elements of atypical E2F targets specifically bind deregulated E2F and
not physiologically activated E2F. (4) Unlike typical E2F targets, promoters of atypical E2F targets are not under repres‐
sion of RB and are specifically activated by deregulated E2F activity.
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4. Regulatory mechanism of promoters is different between typical E2F targets and atypi‐
cal E2F targets. Promoters of typical E2F targets are repressed by E2F/RB complex.
Growth stimulation inactivates RB and releases promoters from the repression by RB.
Thus, so-called activation of typical E2F targets by physiological E2F is ‘release from re‐
pression by RB’. In contrast, activation of atypical E2F targets by deregulated E2F is lit‐
erally ‘activation’. Mutation of EREA, EREK or ERE73s in corresponding full-length
promoter did not enhance basal promoter activities, indicating that these three promot‐
ers are not under repression through the E2F responsive elements. This is consistent
with the observation that binding of physiological E2F to promoters of atypical E2F tar‐
gets was not observed in ChIP assay, including repressor type E2F4 (Figure 9).
It  is  generally accepted that  the amount of  free E2F is  important for differential  regula‐
tion of E2F targets,  which have opposite roles in cell-fate determination, as proposed as
threshold model [100].  According to this model,  when the amount of free E2F (released
from repression of  RB)  is  below the  threshold,  E2F activates  only  growth-related target
genes.  When  the  amount  of  free  E2F  exceeds  the  threshold,  E2F  activates  not  only
growth-related targets but also pro-apoptotic targets.  However,  molecular mechanism of
how different amount of free E2F differentially regulates target genes is not yet elucidat‐
ed. The ‘quantitative’ difference of free E2F seems not sufficient to explain the four differ‐
ences between deregulated E2F and physiologically activated E2F. The above-mentioned
differences strongly suggest the presence of qualitative difference between physiologically
activated E2F by ‘temporal  release’  from RB and deregulated E2F induced by ‘dysfunc‐
tion’ of the RB pathway [75-77] (Figure 9). The ‘qualitative’ difference between both of the
E2Fs seems to be a useful cue to elucidate how cells discriminate oncogenic growth stim‐
ulation from physiological growth stimulation.
5. Conclusion and further research
Accumulating evidence indicates that E2F plays essential roles in cell-fate determination, to
grow, stop or die. Together with G1/S gatekeeper RB, E2F governs control of the restriction
point, deciding whether to grow or not. Upon normal growth stimulation, physiologically acti‐
vated E2F facilitates cell proliferation. Upon dysfunction of the RB pathway, deregulated E2F
suppresses cell growth by inducing p27Kip1 to restrain cells from aberrant cell growth. p21Cip1, in‐
duced by p53 through activation of the ARF gene, may also contribute to suppression of cell
growth. When the arrest mechanism failed to stop the aberrant cell cycle progression, E2F indu‐
ces apoptosis through activation of p53 and TAp73 to protect cells from tumorigenesis. E2F
seems to sense and discriminate between normal growth signals and abnormal growth signals
originating from various oncogenic changes, asking cells whether to grow, stop or die.
Deregulated E2F activity specifically exists in cancer cell lines but not in normal growing fi‐
broblasts, suggesting that deregulated E2F activity may be a useful means to discriminate
abnormally growing cancer cells from physiologically growing normal cells. Since the gen‐
eration of deregulated E2F activity is expected to be based on the mechanism of oncogene‐
sis, deregulated E2F activity could be a universal marker to discriminate cancer cells from
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normal growing cells. Analyses of atypical E2F targets suggest that deregulated E2F might
be qualitatively different from physiologically activated E2F. One of the most intriguing is‐
sues in the future studies would be the molecular nature of deregulated E2F. By elucidating
the molecular nature of deregulated E2F, we might be able to specifically approach cancer
cells without affecting normal growing cells. For this purpose, qualitative difference be‐
tween deregulated E2F and physiological E2F is eager to be elucidated.
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